局部晚期非小细胞肺癌盐酸埃克替尼联合放疗及微波热疗临床观察
发布时间：2019-08-03 19:37
【摘要】：目的表皮生长因子受体络氨酸激酶抑制剂在非小细胞肺癌个性化治疗中的应用受到广泛关注,但目前盐酸埃克替尼联合放疗及微波热疗治疗局部晚期非小细胞肺癌的疗效尚未见报道。本研究旨在对比分析盐酸埃克替尼联合放疗和微波热疗与单纯放疗联合微波热疗治疗晚期非小细胞肺癌疗效及毒副作用。方法选取2013-04-01-2015-03-31青岛市胶州中心医院放疗科收治的36例局部晚期非小细胞肺癌患者作为研究对象。年龄46~69岁,中位年龄56岁。根据EGFR基因突变情况分组,试验组17例,男9例,女8例;对照组19例,男10例,女9例。试验组患者行胸部三维适形放疗DT:50~60Gy,放疗期间联合微波热疗及盐酸埃克替尼(凯美纳),125mg,口服,3次/d。对照组患者进行单纯放疗联合微波热疗。比较两组患者近期疗效及毒副作用。治疗结束后第1、3、6和12个月评价疗效。结果第1个月试验组和对照组PR分别为58.8%和52.6%(χ~2=0.139 3,P=0.709 0),SD分别为41.2%和47.4%(χ~2=0.139 3,P=0.709 0)。第3个月,试验组和对照组PR分别为64.7%和36.8%,(χ~2=3.950 6,P=0.046 9),SD分别为35.3%和26.3%(χ~2=2.184 4,P=0.044 3),PD分别为0和26.3%(χ~2=5.195 2,P=0.022 6),DCR分别为100.0%和63.2%(χ~2=7.775 0,P=0.053),试验组与对照组相比差异均有统计学意义。12个月时试验组部分缓解率(PR)为58.8%,疾病稳定率(SD)为41.2%,无疾病进展(PD);对照组PR为31.6%,SD为47.4%,PD为21.0%。试验组从治疗结束到症状缓解的时间明显少于对照组,P=0.014。试验组中放射性肺炎的发生率为17.6%,对照组为31.6%,对照组放射性肺炎的发生于率高于试验组,P=0.034。结论盐酸埃克替尼联合放疗及微波热疗治疗局部晚期非小细胞肺癌近期疗效优于行单纯放疗联合微波热疗的患者,毒副作用轻。
[Abstract]:Objective the application of epidermal growth factor receptor collaterine kinase inhibitor in individualized treatment of non-small cell lung cancer (NSCLC) has been widely concerned, but the efficacy of facetinib hydrochloric acid combined with radiotherapy and microwave hypertherapy in the treatment of locally advanced non-small cell lung cancer has not been reported. The purpose of this study was to compare the efficacy and side effects of etinib hydrochloric acid combined with radiotherapy and microwave hypertherapy combined with radiotherapy alone in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 36 patients with locally advanced non-small cell lung cancer (NSCLC) treated in radiotherapy Department of Jiaozhou Central Hospital of Qingdao City were selected from 2013 / 04 / 01 / 2015 / 03 / 31. The age was 46 times 69 years old, and the median age was 56 years old. According to the mutation of EGFR gene, there were 17 cases in the experimental group (9 males and 8 females) and 19 cases in the control group (10 males and 9 females). The patients in the experimental group were treated with chest three-dimensional conformal radiotherapy (DT:50~60Gy,) combined with microwave hyperthermic therapy and enetinib hydrochloric acid (Camena), 125mg, oral, 3 times a day. The patients in the control group were treated with radiotherapy alone combined with microwave hyperthermia. The short-term efficacy and side effects of the two groups were compared. The efficacy was evaluated at 1, 3, 6 and 12 months after treatment. Results in the first month, the PR of the experimental group and the control group were 58.8% and 52.6%, respectively (蠂 ~ 2 鈮，
本文编号：2522756
[Abstract]:Objective the application of epidermal growth factor receptor collaterine kinase inhibitor in individualized treatment of non-small cell lung cancer (NSCLC) has been widely concerned, but the efficacy of facetinib hydrochloric acid combined with radiotherapy and microwave hypertherapy in the treatment of locally advanced non-small cell lung cancer has not been reported. The purpose of this study was to compare the efficacy and side effects of etinib hydrochloric acid combined with radiotherapy and microwave hypertherapy combined with radiotherapy alone in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 36 patients with locally advanced non-small cell lung cancer (NSCLC) treated in radiotherapy Department of Jiaozhou Central Hospital of Qingdao City were selected from 2013 / 04 / 01 / 2015 / 03 / 31. The age was 46 times 69 years old, and the median age was 56 years old. According to the mutation of EGFR gene, there were 17 cases in the experimental group (9 males and 8 females) and 19 cases in the control group (10 males and 9 females). The patients in the experimental group were treated with chest three-dimensional conformal radiotherapy (DT:50~60Gy,) combined with microwave hyperthermic therapy and enetinib hydrochloric acid (Camena), 125mg, oral, 3 times a day. The patients in the control group were treated with radiotherapy alone combined with microwave hyperthermia. The short-term efficacy and side effects of the two groups were compared. The efficacy was evaluated at 1, 3, 6 and 12 months after treatment. Results in the first month, the PR of the experimental group and the control group were 58.8% and 52.6%, respectively (蠂 ~ 2 鈮，
本文编号：2522756
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2522756.html
